Loading stock data…
Quince Therapeutics, Inc. (QNCX)
$29.50-1.82 (-5.81%)
Market ClosedLast close Sep 8
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Quince Therapeutics, Inc. in the Healthcare sector is trading at $29.50 with a market capitalization of $19M. Wall Street consensus targets $77.20 (5 analysts), implying a +161.7% move over the next 12 months. The stock is currently near its 52-week low of $15.10, remaining 83.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +161.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$11.11M↑ | -$16.24M↓ | -$11.36M↓ | -$9.89M↑ | -$12.93M |
| Net Income | $35.91M↑ | -$39.46M↓ | -$13.44M↑ | -$16.05M↓ | -$15.03M |
Peer Comparison
JNJUNHPFE
Fundamentals
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$18.97M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-210.80%
Volume
Today's trading volume
12,692
Recent News
Reddit initiated, Caterpillar downgraded: Wall Street's top analyst calls
Reddit initiated, Caterpillar downgraded: Wall Street's top analyst calls
Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy
We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. Quince Therapeutics, Inc. (NASDAQ:QNCX) is among the most popular penny stocks. TheFly reported that QNCX presented Phase 2a clinical results for LAM-001 on May 18, at the American Thoracic Society conference in Orlando, evaluating an inhaled rapamycin formulation […]
BC-Most Active Stocks
Elong Power Holding Ltd. 329,453,698 0.1034
Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure
Quince Therapeutics’ lead asset eDSP failed to meet the primary or secondary endpoints in the pivotal NEAT trial.
Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls
Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls